These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 27613619)

  • 21. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.
    Liang CL; Wang TT; Luby-Phelps K; German DC
    Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell therapy for Parkinson's disease: Functional role of the host immune response on survival and differentiation of dopaminergic neuroblasts.
    Wenker SD; Leal MC; Farías MI; Zeng X; Pitossi FJ
    Brain Res; 2016 May; 1638(Pt A):15-29. PubMed ID: 26239914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson's disease model. Effects of the forced expression of BCL-X(L).
    Ramos-Moreno T; Castillo CG; Martínez-Serrano A
    Behav Brain Res; 2012 Jun; 232(1):225-32. PubMed ID: 22537773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Future drug targets for Parkinson's disease].
    Hirsch EC
    Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in Stem Cells Transplantation for the Therapy of Parkinson's Disease.
    Zeng X; Geng W; Jia J; Wang Z
    Curr Stem Cell Res Ther; 2021; 16(8):958-969. PubMed ID: 33687901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical application of stem cell therapy in Parkinson's disease.
    Politis M; Lindvall O
    BMC Med; 2012 Jan; 10():1. PubMed ID: 22216957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immature Midbrain Dopaminergic Neurons Derived from Floor-Plate Method Improve Cell Transplantation Therapy Efficacy for Parkinson's Disease.
    Qiu L; Liao MC; Chen AK; Wei S; Xie S; Reuveny S; Zhou ZD; Hunziker W; Tan EK; Oh SKW; Zeng L
    Stem Cells Transl Med; 2017 Sep; 6(9):1803-1814. PubMed ID: 28650520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly.
    Luo SX; Huang EJ
    Am J Pathol; 2016 Mar; 186(3):478-88. PubMed ID: 26724386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebral function of bone marrow multipotent adult progenitor cells after transplantation in Parkinson's disease rat models.
    Zhang N; Zhou H; Wang H; Yu L; Li Z; Xu H; Wang M
    Transplant Proc; 2013 Mar; 45(2):719-25. PubMed ID: 23498812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of substantia nigra neurogenesis in homeostasis and dopaminergic degeneration: beneficial effects of the microneurotrophin BNN-20.
    Mourtzi T; Dimitrakopoulos D; Kakogiannis D; Salodimitris C; Botsakis K; Meri DK; Anesti M; Dimopoulou A; Charalampopoulos I; Gravanis A; Matsokis N; Angelatou F; Kazanis I
    Stem Cell Res Ther; 2021 Jun; 12(1):335. PubMed ID: 34112234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SK channel function regulates the dopamine phenotype of neurons in the substantia nigra pars compacta.
    Aumann TD; Gantois I; Egan K; Vais A; Tomas D; Drago J; Horne MK
    Exp Neurol; 2008 Oct; 213(2):419-30. PubMed ID: 18680743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development.
    Hegarty SV; Sullivan AM; O'Keeffe GW
    Dev Biol; 2013 Jul; 379(2):123-38. PubMed ID: 23603197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity-dependent regulation of the dopamine phenotype in substantia nigra neurons.
    Aumann T; Horne M
    J Neurochem; 2012 May; 121(4):497-515. PubMed ID: 22356203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of deep brain stimulation on substantia nigra neurons in a rat model of Parkinson's disease.
    Wu ST; Ma Y; Zhang K; Zhang JG
    Chin Med J (Engl); 2012 Nov; 125(22):4072-5. PubMed ID: 23158145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice.
    Shan X; Chi L; Bishop M; Luo C; Lien L; Zhang Z; Liu R
    Stem Cells; 2006 May; 24(5):1280-7. PubMed ID: 16424396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulating Wnt signaling to improve cell replacement therapy for Parkinson's disease.
    Parish CL; Thompson LH
    J Mol Cell Biol; 2014 Feb; 6(1):54-63. PubMed ID: 24334258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-based therapies for Parkinson's disease.
    Dyson SC; Barker RA
    Expert Rev Neurother; 2011 Jun; 11(6):831-44. PubMed ID: 21651331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.